Report
Olga Smolentseva

BIONTECH: Update from Q1 reporting with the focus on the COVID vaccine | BUY | Under Review

BIONTECH - BUY | Under Review
Update from Q1 reporting with the focus on the COVID vaccine

Financial figures and M&A appetite
What’s next for COVID-19 vaccines?
Underlying
Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch